Understanding and preventing type 1 diabetes through the unique working model of TrialNet

Diabetologia

Volumn 60, Issue 11, 2017, Pages 2139-2147

  Battaglia, Manuela ^a   Anderson, Mark S ^b   Buckner, Jane H ^c   Geyer, Susan M ^d   Gottlieb, Peter A ^e   Kay, Thomas W H ^f,g   Lernmark, Åke ^h   Muller, Sarah ^d   Pugliese, Alberto ⁱ   Roep, Bart O ^j,k   Greenbaum, Carla J ^c   Peakman, Mark ^l,m,n  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f St Vincents Institute   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h LUND UNIVERSITY   (Sweden)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^j CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^k LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^l KING'S COLLEGE LONDON   (United Kingdom)

^m GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

ⁿ KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Autoimmunity; Mechanistic studies; Review; Type 1 diabetes

Indexed keywords

C PEPTIDE; MICRORNA;

CELL KILLING; CLINICAL TRIAL (TOPIC); DISEASE COURSE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; STRESS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; IMMUNOLOGY;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; HUMANS;

EID: 85026746218     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4384-2     Document Type: Review

References (30)

1. Chiang JL, Kirkman MS, Laffel LM, Peters AL (2014) Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 37:2034–2054
2. Bottazzo GF, Florin-Christensen A, Doniach D (1974) Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2:1279–1283
3. Atkinson MA, Eisenbarth GS, Michels AW (2014) Type 1 diabetes. Lancet 383:69–82
4. Vehik K, Beam CA, Mahon JL et al (2011) Development of autoantibodies in the TrialNet Natural History Study. Diabetes Care 34:1897–1901
5. Insel RA, Dunne JL, Atkinson MA et al (2015) Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38:1964–1974
6. Skyler JS, Greenbaum CJ, Lachin JM et al (2008) Type 1 Diabetes TrialNet—an international collaborative clinical trials network. Ann N Y Acad Sci 1150:14–24
7. Nokoff N, Rewers M (2013) Pathogenesis of type 1 diabetes: lessons from natural history studies of high-risk individuals. Ann N Y Acad Sci 1281:1–15
8. Battaglia M, Atkinson MA (2015) The streetlight effect in type 1 diabetes. Diabetes 64:1081–1090
9. Davis AK, DuBose SN, Haller MJ et al (2015) Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care 38:476–481
10. Atkinson MA, von Herrath M, Powers AC, Clare-Salzler M (2015) Current concepts on the pathogenesis of type 1 diabetes--considerations for attempts to prevent and reverse the disease. Diabetes Care 38:979–988
11. Stokes JR, Casale TB (2016) Characterization of asthma endotypes: implications for therapy. Ann Allergy Asthma Immunol 117:121–125
12. Arif S, Leete P, Nguyen V et al (2014) Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes 63:3835–3845
13. Akirav EM, Lebastchi J, Galvan EM et al (2011) Detection of beta cell death in diabetes using differentially methylated circulating DNA. Proc Natl Acad Sci U S A 108:19018–19023
14. Herold KC, Usmani-Brown S, Ghazi T et al (2015) Beta cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest 125:1163–1173
15. Mirmira RG, Sims EK, Syed F, Evans-Molina C (2016) Biomarkers of beta-cell stress and death in type 1 diabetes. Curr Diab Rep 16:95
16. Marre ML, James EA, Piganelli JD (2015) β cell ER stress and the implications for immunogenicity in type 1 diabetes. Front Cell Dev Biol 3:67
17. Evans-Molina C, Hatanaka M, Mirmira RG (2013) Lost in translation: endoplasmic reticulum stress and the decline of β-cell health in diabetes mellitus. Diabetes Obes Metab 15(Suppl 3):159–169
18. Sims EK, Chaudhry Z, Watkins R et al (2016) Elevations in the fasting serum proinsulin-to-C-peptide ratio precede the onset of type 1 diabetes. Diabetes Care 39:1519–1526
19. Rodriguez-Calvo T, Zapardiel-Gonzalo J, Amirian N et al (2017) Increase in pancreatic proinsulin and preservation of beta cell mass in autoantibody positive donors prior to type 1 diabetes onset. Diabetes 66:1334–1345
20. Snowhite IV, Allende G, Sosenko J, Pastori RL, Messinger Cayetano S, Pugliese A (2017) Association of serum microRNAs with islet autoimmunity, disease progression and metabolic impairment in relatives at risk of type 1 diabetes. Diabetologia doi:10.1007/s00125-017-4294-3
21. Orban T, Bundy B, Becker DJ et al (2014) Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 37:1069–1075
22. Orban T, Beam CA, Xu P et al (2014) Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline. Diabetes 63:3449–3457
23. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361:2143–2152
24. Pescovitz MD, Greenbaum CJ, Bundy B et al (2014) B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care 37:453–459
25. Chamberlain N, Massad C, Oe T, Cantaert T, Herold KC, Meffre E (2016) Rituximab does not reset defective early B cell tolerance checkpoints. J Clin Invest 126:282–287
26. Smith MJ, Packard TA, O’Neill SK et al (2015) Loss of anergic B cells in prediabetic and new-onset type 1 diabetic patients. Diabetes 64:1703–1712
27. Valle A, Giamporcaro GM, Scavini M et al (2013) Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. Diabetes 62:2072–2077
28. Bollyky JB, Xu P, Butte AJ, Wilson DM, Beam CA, Greenbaum CJ (2015) Heterogeneity in recent-onset type 1 diabetes—a clinical trial perspective. Diabetes Metab Res Rev 31:588–594
29. Cabrera SM, Chen YG, Hagopian WA, Hessner MJ (2016) Blood-based signatures in type 1 diabetes. Diabetologia 59:414–425
30. Chen YG, Cabrera SM, Jia S et al (2014) Molecular signatures differentiate immune states in type 1 diabetic families. Diabetes 63:3960–3973